ReNeuron Group plc is a UK-based company that specializes in cell-based therapies. Their flagship product is the CTX stem cell therapy candidate, which is currently in the partnering stage in China and other countries for treating stroke disability. The company is also working on a human retinal progenitor cell therapy, which is currently in Phase I/IIa clinical trials to treat retinitis pigmentosa, a disease that causes blindness. ReNeuron Group plc is quickly becoming a major player in the field of cell-based therapies with their innovative and potentially life-changing treatments.